文献速递肝病消化道肿瘤与早癌

瑞戈非尼联合帕博利珠单抗一线治疗晚期肝细胞癌的多中心1b期剂量探索/扩展研究

A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2025-11-10

这项多中心1b期研究评估瑞戈非尼联合帕博利珠单抗一线治疗晚期肝细胞癌的安全性,主要终点为安全性。瑞戈非尼最大耐受剂量为120 mg/日联合帕博利珠单抗,总体安全队列最常见不良事件为腹泻和乏力,54例可评估患者客观缓解率31%、疾病控制率89%。

要点

  • 瑞戈非尼联合帕博利珠单抗一线治疗晚期肝细胞癌安全性可控。
  • 瑞戈非尼最大耐受剂量为120 mg/日联合帕博利珠单抗200 mg每3周。
  • 54例可评估患者客观缓解率31%,疾病控制率89%。

核心结论

  • 瑞戈非尼联合帕博利珠单抗一线治疗晚期肝细胞癌可行,安全性可控,客观缓解率和疾病控制率与其他免疫联合方案一致。

研究设计与样本

  • 多中心剂量探索/扩展1b期研究,纳入未接受过系统治疗的晚期肝细胞癌成人患者。
  • 剂量探索阶段接受瑞戈非尼80 mg/日联合帕博利珠单抗,扩展队列接受瑞戈非尼80或120 mg/日联合帕博利珠单抗。
  • 瑞戈非尼每日用药3周,帕博利珠单抗200 mg每3周,4周为一周期。
  • 主要终点为安全性,抗肿瘤活性为次要终点;总体安全队列57例,疗效可评估54例。

主要发现

  • 瑞戈非尼最大耐受剂量为120 mg/日联合帕博利珠单抗;19例接受120 mg/日联合治疗的患者中4例出现剂量限制性毒性。
  • 剂量限制性毒性包括3级AST升高伴1/2级胆红素升高(2例)和3级皮疹(2例)。
  • 总体安全队列最常见治疗中出现的不良事件为腹泻(53%)和乏力(51%)。
  • 最常见的≥3级治疗中出现的不良事件为AST升高(18%)和高血压(16%)。
  • 54例可评估患者客观缓解率为31%,疾病控制率为89%。

关键数值与推荐

  • 瑞戈非尼最大耐受剂量为120 mg/日联合帕博利珠单抗200 mg每3周。
  • 总体安全队列(n=57)腹泻发生率53%,乏力发生率51%。
  • ≥3级AST升高发生率18%,≥3级高血压发生率16%。
  • 54例可评估患者客观缓解率31%,疾病控制率89%。

临床怎么用

  • 瑞戈非尼联合帕博利珠单抗可作为晚期肝细胞癌一线治疗的可行选择,需关注腹泻、乏力、AST升高和高血压等不良事件。
  • 因不良事件进行剂量调整在瑞戈非尼80 mg/日联合组少于120 mg/日联合组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Combinations including an immune checkpoint inhibitor are preferred first-line treatments for advanced HCC. We investigated the safety of regorafenib plus pembrolizumab as first-line systemic therapy for advanced HCC. APPROACH AND RESULTS: This was a dose-defining/expansion phase 1b study in adults with advanced HCC without prior systemic treatment. Patients received regorafenib 80 or 120 mg/day for 3 weeks plus pembrolizumab 200 mg every 3 weeks in 4-week cycles (rego-80/pembro or rego-120/pembro): rego-80/pembro in the dose-defining phase; rego-80/pembro or rego-120/pembro in 2 dose-expansion cohorts. The primary objective was to assess safety; antitumor activity was a secondary objective. The MTD of regorafenib was 120 mg/day plus pembrolizumab; 4/19 patients receiving rego-120/pembro experienced dose-limiting toxicities [grade 3 increased AST with grade 1/2 increased bilirubin (n=2), and grade 3 rash (n=2)]. The most common treatment-emergent adverse events (TEAEs) in the overall safety cohort (n=57) were diarrhea (53%) and fatigue (51%). The most common grade ≥3 TEAEs were increased AST (18%) and hypertension (16%). Dose modifications due to study drug-related adverse events were less frequent with rego-80/pembro than with rego-120/pembro. The objective response rate (ORR) in 54 response-evaluable patients was 31% and the disease control rate (DCR) was 89%. Exploratory analyses suggested an association between lower angiogenesis and transforming growth factor-β signaling before treatment and response. CONCLUSIONS: Treatment with rego/pembro is feasible in patients with advanced HCC with a manageable safety profile. ORR and DCR are promising and consistent with other immunotherapy combinations in this setting.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. El-Khoueiry AB, Kim RD, Harris WP, et al. A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma. Hepatology. 2025. PMID: 41213032. doi:10.1097/HEP.0000000000001585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。